What is Halozyme Therapeutics, Inc.'s Market Cap?

Halozyme Therapeutics, Inc.'s Market Cap is $14.3B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Enterprise Value?

Halozyme Therapeutics, Inc.'s Enterprise Value is $16.2B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Trailing P/E?

Halozyme Therapeutics, Inc.'s Trailing P/E is 34.5×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Price / Sales?

Halozyme Therapeutics, Inc.'s Price / Sales is 8.6×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EV / Revenue?

Halozyme Therapeutics, Inc.'s EV / Revenue is 9.8×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EV / EBITDA?

Halozyme Therapeutics, Inc.'s EV / EBITDA is 26.5×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Revenue (TTM)?

Halozyme Therapeutics, Inc.'s Revenue (TTM) is $1.7B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Net Income (TTM)?

Halozyme Therapeutics, Inc.'s Net Income (TTM) is $413.6M, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EBITDA?

Halozyme Therapeutics, Inc.'s EBITDA is $611.8M, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Diluted EPS (TTM)?

Halozyme Therapeutics, Inc.'s Diluted EPS (TTM) is 3.64, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Halozyme Therapeutics, Inc.

XNAS · usd

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG001SGX585

125.63▲ 1.09 (0.88%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA

Financial Highlights

Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt

Trading Information

Previous Close: 124.54
Day's Range: 123.74 – 126.23
52-Week Range: 61.23 – 126.23
Volume: 1.5M
Avg Volume: 2.6M

Share Statistics

Shares Outstanding
Employees: 423
Exchange: XNAS
Listed: 2004-03-12

Share count as of July 31, 2026

Halozyme Therapeutics, Inc. (HALO) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Halozyme Therapeutics, Inc. (HALO)

What is Halozyme Therapeutics, Inc.'s Market Cap?: Halozyme Therapeutics, Inc.'s Market Cap is $14.3B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Enterprise Value?: Halozyme Therapeutics, Inc.'s Enterprise Value is $16.2B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Trailing P/E?: Halozyme Therapeutics, Inc.'s Trailing P/E is 34.5×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Price / Sales?: Halozyme Therapeutics, Inc.'s Price / Sales is 8.6×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EV / Revenue?: Halozyme Therapeutics, Inc.'s EV / Revenue is 9.8×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EV / EBITDA?: Halozyme Therapeutics, Inc.'s EV / EBITDA is 26.5×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Revenue (TTM)?: Halozyme Therapeutics, Inc.'s Revenue (TTM) is $1.7B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Net Income (TTM)?: Halozyme Therapeutics, Inc.'s Net Income (TTM) is $413.6M, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EBITDA?: Halozyme Therapeutics, Inc.'s EBITDA is $611.8M, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Diluted EPS (TTM)?: Halozyme Therapeutics, Inc.'s Diluted EPS (TTM) is 3.64, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · HALOAs-filed SEC (XBRL) data